Hussein Khan
Internal Medicine · New York, NYNPI 1023428398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,448, 4.3 times the $337 reported in 2023.
Across 108 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$392
- Viiv Healthcare Company$387
- Boehringer Ingelheim$277
- AbbVie$249
- Exact Sciences$191
- Lilly USA, LLC$160
- plus $926 from 16 others
What the payments were for
- Food & beverage$2,583100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $392 |
| Viiv Healthcare Company | 17 | $387 |
| Boehringer Ingelheim | 10 | $277 |
| AbbVie | 10 | $249 |
| Exact Sciences | 7 | $191 |
| Lilly USA, LLC | 8 | $160 |
| Merck | 6 | $157 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $157 |
| Gilead | 9 | $150 |
| Intercept Pharmaceuticals, Inc. | 3 | $69 |
| Astellas Pharma US Inc | 2 | $61 |
| Sanofi | 2 | $59 |
| Hologic Sales And Service, LLC | 2 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Amgen | 1 | $26 |
| Madrigal Pharmaceuticals | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Pfizer | 1 | $23 |
| Phadia US Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$125
How this compares
$2,583 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $3,261 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $415 |
| Levothyroxine Sodium | 24 | $264 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 12 | $201 |
| Omeprazole | 16 | $155 |
| Atorvastatin Calcium | 17 | $150 |
| Lisinopril | 13 | $117 |
| Montelukast Sodium | 15 | $74 |
| Azithromycin | 21 | $67 |
| Amlodipine Besylate | 11 | $51 |
| Escitalopram Oxalate | 11 | $45 |
| Metformin Hcl | 16 | $32 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.